Hill Helicopters engineered composite main rotor blades using a novel single-cure manufacturing process for stiffness and ...
Released every 12 to 18 months, 3D NAND scaling outpaces most other semiconductor devices in replacement rate and performance ...
For decades, caribou in Jasper National Park have been declining, and experts warned that without intervention, they would ...
Steel Horse Rides on MSN
Space Forge produces plasma for low-Earth-orbit chip manufacturing
Space Forge has positioned itself as a specialist in off‑planet manufacturing, building satellites designed not just to ...
MANILA, Philippines — A flood control structure worth more than P87 million in Surigao del Norte collapsed just three years after it finished construction, even without consistent rainfall and strong ...
Modern passenger airliners are essentially tubes-with-wings, they just happen to be tubes that are stuffed full with fancy ...
SAN FRANCISCO, Dec. 07, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Structure Therapeutics Inc. earns a Strong Buy rating following robust phase 2b data for oral GLP-1R agonist Aleniglipron in obesity. Aleniglipron achieved placebo-adjusted weight loss up to -15.3% at ...
Tech Xplore on MSN
One pull of a string is all it takes to deploy these complex structures
MIT researchers have developed a new method for designing 3D structures that can be transformed from a flat configuration ...
SAN FRANCISCO, Dec. 08, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for ...
Lauren (Hansen) Holznienkemper is a lead editor for the small business vertical at Forbes Advisor, specializing in HR, payroll and recruiting solutions for small businesses. Using research and writing ...
Placebo-adjusted mean weight loss of 11.3% (27.3 lbs) with 120 mg dose in the 36-week Phase 2b ACCESS study with a 10.4% adverse event-related treatment discontinuation Placebo-adjusted mean weight ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results